141083-85-4

Upstream product

• 794514-81-1 (S)-methyl 2-(2-nitrophenylsulfonamido)pent-4-enoate 
• 50299-15-5 methyl (S)-allylglycinate 
• 282527-09-7 methyl (S)-1-(4-nitrobenzenesulfonyl)-1,2,3,6-tetrahydropyridine-2-carboxylate 
• 282527-06-4 methyl 2-[(1-benzyloxyallyl)-(4-nitrobenzenesulfonyl)amino]-(S)-pent-4-enoate 
• 282527-08-6 methyl (2S)-6-benzyloxy-1-(4-nitrobenzenesulfonyl)-1,2,3,6-tetrahydropyridine-2-carboxylate 

Downstream Products

• 144090-39-1 1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-1,2,3,6-tetrahydro-pyridine-2-carboxylic acid methyl ester 
• 145981-40-4 4,5-epoxy-2-piperidinecarboxylic acid-methyl ester 
• 144090-43-7 [(S)-1-Benzyl-2-((1S,4S,5S)-4-iodo-7-oxo-6-oxa-2-aza-bicyclo[3.2.1]oct-2-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 144090-41-5 (S)-1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-1,2,3,6-tetrahydro-pyridine-2-carboxylic acid 
• 31456-71-0 (2S)-1,2,3,6-tetrahydropyridine-2-carboxylic acid 
• 144090-43-7 [(R)-1-Benzyl-2-((4S,5S)-4-iodo-7-oxo-6-oxa-2-aza-bicyclo[3.2.1]oct-2-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 144090-41-5 1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-1,2,3,6-tetrahydro-pyridine-2-carboxylic acid 
• 144090-45-9 (S)-2-((2S,3S)-2-{[(2R,4R,5R)-4-Acetoxy-1-((S)-2-tert-butoxycarbonylamino-3-phenyl-propionyl)-5-iodo-piperidine-2-carbonyl]-amino}-3-methyl-pentanoylamino)-3-methyl-butyric acid methyl ester 
• 144090-44-8 (S)-2-((2S,3S)-2-{[(2S,4S,5S)-1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-4-hydroxy-5-iodo-piperidine-2-carbonyl]-amino}-3-methyl-pentanoylamino)-3-methyl-butyric acid methyl ester 
• 144090-44-8 (S)-2-((2S,3S)-2-{[(2R,4R,5R)-1-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-4-hydroxy-5-iodo-piperidine-2-carbonyl]-amino}-3-methyl-pentanoylamino)-3-methyl-butyric acid methyl ester 
• 144090-46-0 C₄₃H₆₆IN₇O₁₃ 
• 144090-47-1 Boc-Ser-Ala-Ala-Phe-3S-OAc-Δ-4,5-(L)-Pip-Ile-Val-OMe 

Relevant academic research and scientific papers

SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with

Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52

The FK506-binding proteins (FKBP) 51 and 52 are cochaperones that modulate the signal transduction of steroid hormone receptors. Both proteins have been implicated in prostate cancer. Furthermore, single nucleotide polymorphisms in the gene encoding FKBP51 have been associated with a variety of psychiatric disorders. Rapamycin and FK506 are two macrocyclic natural products that bind to these proteins indiscriminately but with nanomolar affinity. We here report the cocrystal structure of FKBP51 with a simplified α-ketoamide analogue derived from FK506 and the first structure-activity relationship analysis for FKBP51 and FKBP52 based on this compound. In particular, the tert-pentyl group of this ligand was systematically replaced by a cyclohexyl ring system, which more closely resembles the pyranose ring in the high-affinity ligands rapamycin and FK506. The interaction with FKBPs was found to be surprisingly tolerant to the stereochemistry of the attached cyclohexyl substituents. The molecular basis for this tolerance was elucidated by X-ray cocrystallography.

A ring-closing metathesis-mediated route to novel enantiopure conformationally restricted cyclic amino acids

A combination of palladium-catalysed N,O-acetal formation, ruthenium- catalysed ring-closing metathesis and N-sulfonyliminium ion-mediated C-C bond formation constitutes an efficient and versatile route to a set of enantiomerically pure 2,6-disubstituted unsaturated pipecolic acid derivatives.